Ahmed Shawky Elserafy1, Ahmed Bendary2, Atef Elbahry3, Elsayed Farag4, Tamer Mostafa4, Osama Sanad5, Ahmed Elkersh6, Mohammed Selim7, Hany Ragy7, Hazem Khamis8, Waleed Abdo6, Ashraf Reda6. 1. Department of Cardiology, Ain Shams University, Cairo, Egypt. 2. Department of Cardiology, Benha University, Behna, Egypt. ahmed.bendari@fmed.bu.edu.eg. 3. Cardiology Unit, Port Foad Centre, Port Foad, Egypt. 4. Department of Cardiology, Zagazig University, Zagazig, Egypt. 5. Department of Cardiology, Benha University, Behna, Egypt. 6. Department of Cardiology, Menufiya University, Menufiya, Egypt. 7. Department of Cardiology, National Heart Institute, Cairo, Egypt. 8. Department of Cardiology, MTI University, Cairo, Egypt.
Abstract
BACKGROUND: Elevation of low-density lipoprotein cholesterol (LDL-c) is still a hugely unmet need in the reduction of atherosclerotic cardiovascular disease. In the published CardioRisk project in Egypt, up to 71% of female participants had dyslipidemia. Control of LDL-c levels and thus improvement of hyperlipidemia is quite often very difficult. With the introduction of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, the decrease of significant cardiac adverse events, the patient control rate, and the death rate have all been improved. Inhibition of the formation of PCSK9 through inclisiran, which is a novel method of reducing LDL-c and is only given twice per year, seems alluring. After revision of published data, we analyzed the potential advantages of the use of inclisiran. CONCLUSION: The Egyptian Association for Vascular Biology and Atherosclerosis (EAVA) analyzed the data necessary for obtaining clear indications for the usage of inclisiran. We propose the addition of inclisiran to statins with or without ezetimibe for patients with documented atherosclerotic cardiovascular disease (ASCVD) or similar risk, familial hypercholesterolemia (FH) with another major risk factor, and very high and high risk diabetes mellitus, who did not reach LDL-c goals and/or with true statin intolerance. Inclisiran is also recommended as upfront therapy, with triple combination, in extreme risk subjects such as those with post acute coronary syndromes (ACS).
BACKGROUND: Elevation of low-density lipoprotein cholesterol (LDL-c) is still a hugely unmet need in the reduction of atherosclerotic cardiovascular disease. In the published CardioRisk project in Egypt, up to 71% of female participants had dyslipidemia. Control of LDL-c levels and thus improvement of hyperlipidemia is quite often very difficult. With the introduction of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, the decrease of significant cardiac adverse events, the patient control rate, and the death rate have all been improved. Inhibition of the formation of PCSK9 through inclisiran, which is a novel method of reducing LDL-c and is only given twice per year, seems alluring. After revision of published data, we analyzed the potential advantages of the use of inclisiran. CONCLUSION: The Egyptian Association for Vascular Biology and Atherosclerosis (EAVA) analyzed the data necessary for obtaining clear indications for the usage of inclisiran. We propose the addition of inclisiran to statins with or without ezetimibe for patients with documented atherosclerotic cardiovascular disease (ASCVD) or similar risk, familial hypercholesterolemia (FH) with another major risk factor, and very high and high risk diabetes mellitus, who did not reach LDL-c goals and/or with true statin intolerance. Inclisiran is also recommended as upfront therapy, with triple combination, in extreme risk subjects such as those with post acute coronary syndromes (ACS).
Authors: Kausik K Ray; Laurens F Reeskamp; Ulrich Laufs; Maciej Banach; François Mach; Lale S Tokgözoğlu; Derek L Connolly; Anja J Gerrits; Erik S G Stroes; Luis Masana; John J P Kastelein Journal: Eur Heart J Date: 2022-02-22 Impact factor: 29.983
Authors: Kausik K Ray; R Scott Wright; David Kallend; Wolfgang Koenig; Lawrence A Leiter; Frederick J Raal; Jenna A Bisch; Tara Richardson; Mark Jaros; Peter L J Wijngaard; John J P Kastelein Journal: N Engl J Med Date: 2020-03-18 Impact factor: 91.245
Authors: Maurizio Averna; Maciej Banach; Eric Bruckert; Heinz Drexel; Michel Farnier; Dan Gaita; Paolo Magni; Winfried März; Luis Masana; Alberto Mello E Silva; Zeljko Reiner; Emilio Ros; Michal Vrablik; Alberto Zambon; Jose L Zamorano; Jane K Stock; Lale S Tokgözoğlu; Alberico L Catapano Journal: Atherosclerosis Date: 2021-04-13 Impact factor: 5.162
Authors: Alanna M Chamberlain; Yan Gong; Kathryn McAuliffe Shaw; Jiang Bian; Wen-Liang Song; MacRae F Linton; Vivian Fonseca; Eboni Price-Haywood; Emily Guhl; Jordan B King; Rashmee U Shah; Jon Puro; Elizabeth Shenkman; Pamala A Pawloski; Karen L Margolis; Adrian F Hernandez; Rhonda M Cooper-DeHoff Journal: J Am Heart Assoc Date: 2019-05-07 Impact factor: 5.501
Authors: Frederick J Raal; David Kallend; Kausik K Ray; Traci Turner; Wolfgang Koenig; R Scott Wright; Peter L J Wijngaard; Danielle Curcio; Mark J Jaros; Lawrence A Leiter; John J P Kastelein Journal: N Engl J Med Date: 2020-03-18 Impact factor: 91.245